查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1563974

全球骨髓移植市場

Bone Marrow Transplant
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2030年全球骨髓移植市場將達147億美元

2023年全球骨髓移植市場預計為111億美元，預計到2030年將達到147億美元，2023-2030年分析期間複合年成長率為4.1%。骨髓瘤適應症是本報告分析的細分市場之一，預計複合年成長率為 4.1%，到分析期結束時將達到 48 億美元。分析期間，白血病適應症細分市場的複合年成長率預計為 4.4%。

美國市場預估29億美元，中國預期複合年成長率6.3%

預計2023年美國骨髓移植市場規模將達29億美元。中國作為世界第二大經濟體，預計2030年市場規模將達31億美元，2023-2030年分析期間複合年成長率為6.3%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 2.7% 和 3.3%。在歐洲，德國的複合年成長率預計為 3.2%。

全球骨髓移植市場－主要趨勢與促進因素總結

骨髓移植如何挽救生命以及為什麼它很重要？

骨髓移植（BMT）是一種緊急醫療程序，在治療各種危及生命的疾病，特別是白血病、淋巴瘤和多發性骨髓瘤等血癌方面發揮著至關重要的作用。這種治療方法以健康的幹細胞取代受損或患病的骨髓，使血液和免疫系統再生，並為患者提供第二次生命機會。骨髓移植包括自體骨髓移植和同種異體骨髓移植，自體骨髓移植是採集患者自身的幹細胞，經過處理後返回體內，而同種異體骨髓移植是從親屬或無關的捐贈者提供幹細胞。這些方法之間的選擇取決於患者的病情、合適的捐贈者的可用性以及所治療的特定疾病。除了在癌症治療中發揮重要作用外，BMT 還用於治療嚴重的血液疾病，如鐮狀細胞疾病和地中海貧血。這種治療方法正在徹底改變血液學領域，並為先前治療選擇有限的患者帶來希望。

骨髓移植的進展和技術如何？

多年來骨髓移植技術的進步顯著改善了患者的治療效果並擴大了可治療疾病的範圍。主要創新之一是 RIC（低強度調節）植入的發展。這使得老年患者和患有其他健康問題的患者能夠接受較低劑量的化療和放射線治療的骨髓移植。這種方法降低了與傳統高劑量預處理方案相關的風險，並允許更多患者接受 BMT。另一個重要的進步是半相合移植的使用，其中供體與受體僅半匹配。這項技術大大增加了潛在捐贈者的數量，使患者更容易找到匹配的捐贈者，特別是在完美匹配很少見的不同種族人群中。此外，周邊血幹細胞和臍帶血等幹細胞採集方法的改進增加了可用幹細胞來源的數量，每種幹細胞來源在植入速度和免疫恢復方面都具有優勢。這些技術進步提高了骨髓移植的有效性、安全性和可近性。

骨髓移植有哪些挑戰和併發症？

儘管骨髓移植具有挽救生命的潛力，但該手術並非沒有重大挑戰和風險。最嚴重的併發症之一是移植物抗宿主疾病（GVHD），這是一種危及生命的疾病，當捐贈的幹細胞攻擊接受者的身體時，會影響皮膚、肝臟和胃腸道，這是一種潛在威脅的疾病。免疫抑制治療和移植後護理的進步有助於控制和降低 GVHD 的嚴重程度，但它仍然是一個主要問題，特別是在同種異體移植中。另一個問題是移植後免疫恢復期間感染的高風險。這是因為患者由於免疫系統受到抑製而極其脆弱。預防性抗生素和抗病毒藥物的開發改善了感染控制，但需要密切注意和監測。此外，骨髓移植的成功很大程度上取決於捐贈者和受體的兼容性，找到合適的匹配可能很困難，特別是對於少數族裔患者而言。最後，該手術費用昂貴且資源密集，限制了全世界許多患者的使用，特別是在資源匱乏的環境中。解決這些挑戰對於提高骨髓移植的整體成功率和可近性至關重要。

骨髓移植市場擴大的驅動力是什麼？

骨髓移植市場的成長是由反映醫療技術進步和醫療保健需求變化的多個因素所推動的。血癌和其他血液疾病的盛行率不斷增加，增加了對骨髓移植作為治療選擇的需求。技術進步，例如改進的配對技術和擴大的捐贈者登記冊，使找到相容的捐贈者變得更容易，並提高了移植的可用性和成功率。個人化醫療的興起也推動了這個市場的成長，它可以根據每個患者的基因特徵來客製化治療方案，從而實現更精確的匹配和更好的治療結果。此外，人口老化也有助於市場擴張。這是因為，由於降低強度訓練等技術的進步，患有骨髓發育不良症候群等疾病的老年人擴大接受移植。此外，人們對捐贈者登記重要性的認知不斷提高以及公共和私人臍帶血庫的擴張正在增加幹細胞的可用性，並使更多患者更容易獲得移植。最後，醫療保健支出和研發投資的增加正在刺激該行業的創新，進一步推動市場成長並改善患者的治療結果。

受訪企業範例（38家知名企業）

  • Allcells LLC
  • American Type Culture Collection（ATCC）
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis US LLC

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP10772

Global Bone Marrow Transplant Market to Reach US$14.7 Billion by 2030

The global market for Bone Marrow Transplant estimated at US$11.1 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Myeloma Indication, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Leukemia Indication segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 6.3% CAGR

The Bone Marrow Transplant market in the U.S. is estimated at US$2.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Bone Marrow Transplant Market - Key Trends and Drivers Summarized

How Does Bone Marrow Transplant Save Lives and Why Is It Crucial?

Bone marrow transplant (BMT) is a life-saving medical procedure that plays a pivotal role in the treatment of various life-threatening diseases, particularly blood cancers such as leukemia, lymphoma, and multiple myeloma. The procedure involves replacing damaged or diseased bone marrow with healthy stem cells, which can regenerate the blood and immune system, offering patients a second chance at life. There are two main types of bone marrow transplants: autologous, where the patient’s own stem cells are harvested, treated, and then returned to their body, and allogeneic, where the stem cells are donated by another person, often a relative or a matched unrelated donor. The choice between these methods depends on the patient’s condition, the availability of a suitable donor, and the specific disease being treated. BMT is not only essential for treating cancer but is also used to manage severe blood disorders such as aplastic anemia and genetic conditions like sickle cell disease and thalassemia. This procedure has been transformative in the field of hematology, offering hope to patients who once had limited treatment options.

What Are the Advancements and Techniques in Bone Marrow Transplantation?

Over the years, advancements in bone marrow transplantation techniques have significantly improved patient outcomes and expanded the range of treatable conditions. One of the major innovations is the development of reduced-intensity conditioning (RIC) transplants, which allow older patients or those with other health issues to undergo the procedure with lower doses of chemotherapy and radiation. This approach has made BMT accessible to a broader patient population, reducing the risks associated with traditional high-dose conditioning regimens. Another significant advancement is the use of haploidentical transplants, where a donor is only a half-match to the recipient. This technique has greatly increased the pool of potential donors, making it easier for patients to find a match, particularly in ethnically diverse populations where full matches may be rare. Additionally, improvements in stem cell harvesting, including the use of peripheral blood stem cells and cord blood, have provided more options for stem cell sources, each with its own set of benefits in terms of engraftment speed and immune recovery. These technological advancements have collectively enhanced the effectiveness, safety, and accessibility of bone marrow transplants.

What Challenges and Complications Are Associated with Bone Marrow Transplants?

Despite the life-saving potential of bone marrow transplants, the procedure is not without significant challenges and risks. One of the most serious complications is graft-versus-host disease (GVHD), which occurs when the donated stem cells attack the recipient’s body, leading to potentially life-threatening conditions affecting the skin, liver, and gastrointestinal tract. Advances in immunosuppressive therapies and post-transplant care have helped to manage and mitigate the severity of GVHD, but it remains a major concern, particularly in allogeneic transplants. Another challenge is the high risk of infection during the period of immune recovery post-transplant, as patients are extremely vulnerable due to the suppression of their immune systems. The development of prophylactic antibiotics and antiviral drugs has improved infection control, but it requires meticulous care and monitoring. Additionally, the success of a bone marrow transplant heavily depends on the compatibility between donor and recipient, and finding a suitable match can be difficult, especially for patients from minority ethnic backgrounds. Lastly, the procedure is expensive and resource-intensive, limiting access for many patients globally, especially in low-resource settings. Addressing these challenges is critical to improving the overall success rates and accessibility of bone marrow transplants.

What’s Fueling the Expansion of the Bone Marrow Transplant Market?

The growth in the bone marrow transplant market is driven by several factors that reflect advancements in medical technology and changing healthcare demands. The increasing prevalence of blood cancers and other hematological disorders has led to a higher demand for bone marrow transplants as a treatment option. Technological advancements, such as the development of improved matching techniques and the expansion of donor registries, have made it easier to find compatible donors, increasing the availability and success rates of transplants. The rise of personalized medicine, which tailors treatments to the genetic profile of individual patients, is also driving growth in this market, as it enables more precise matching and better outcomes. Moreover, the aging population is contributing to the market expansion, as older adults with conditions like myelodysplastic syndromes are increasingly undergoing transplants thanks to advancements like reduced-intensity conditioning. Additionally, growing awareness of the importance of donor registration and the expansion of public and private cord blood banks are increasing the availability of stem cells, making transplants more accessible to a wider patient population. Finally, increased healthcare spending and investment in research and development are fueling innovation in this field, further propelling market growth and improving patient outcomes.

Select Competitors (Total 38 Featured) -

  • Allcells LLC
  • American Type Culture Collection (ATCC)
  • Beike Biotechnology Co., Ltd.
  • BioTime, Inc.
  • Cellular Dynamics International
  • Corestem, Inc.
  • Gamida Cell Ltd.
  • HemaCare Corporation
  • Lifeline Cell Technology
  • Lonza Group Ltd.
  • Mesoblast Ltd.
  • Promocell GmbH
  • ReachBio LLC
  • Sanofi-aventis U.S. LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bone Marrow Transplant - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Blood Cancers Drives Demand for Bone Marrow Transplants
    • Advancements in Stem Cell Harvesting Techniques Propel Growth in Bone Marrow Transplant Procedures
    • Rising Success Rates and Improved Outcomes Strengthen Business Case for Bone Marrow Transplants
    • Expansion of Donor Registries and Matching Technologies Expands Addressable Market Opportunity
    • Growing Use of Cord Blood as a Stem Cell Source Drives Adoption of Bone Marrow Transplant Procedures
    • Technological Innovations in Immunosuppressive Treatments Propel Growth in Allogeneic Transplants
    • Rising Awareness and Education About Bone Marrow Donation Generate Increased Donor Participation
    • Challenges in Managing Graft-Versus-Host Disease (GVHD) Create Opportunities for Innovation in Post-Transplant Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bone Marrow Transplant Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bone Marrow Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • JAPAN
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • CHINA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • EUROPE
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bone Marrow Transplant by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • FRANCE
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • GERMANY
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bone Marrow Transplant by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • INDIA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bone Marrow Transplant by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bone Marrow Transplant by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bone Marrow Transplant by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030
  • AFRICA
    • Bone Marrow Transplant Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bone Marrow Transplant by Indication - Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bone Marrow Transplant by Indication - Percentage Breakdown of Value Sales for Myeloma, Leukemia, Lymphoma, Thalassemia and Other Indications for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bone Marrow Transplant by Transplant Type - Autologous and Allogeneic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bone Marrow Transplant by Transplant Type - Percentage Breakdown of Value Sales for Autologous and Allogeneic for the Years 2014, 2024 & 2030

IV. COMPETITION